ProfessorGlenn Jacobson

Head, School of Pharmacy and Pharmacology

Pharmacy

  • Head, School of Pharmacy and Pharmacology
    Pharmacy
  • +61 3 6226 2202 (Work)
  • +61 3 6226 2870 (Fax)
  • School of Pharmacy and Pharmacology, Pharmacy, 4016 Pharmacy Building, Sandy Bay Campus, TAS

FUNDED PROJECTS

  • GRANT
    Detection and quantification of common beta2-agonists after inhaled administration in humans with dried blood spots and dried plasma spots
    24 Jul 2023 - 24 Jul 2024
    People funded by this grant:
    • Jacobson G,
    • Hostrup M,
    • Dehnes Y,
    • Thevis M
    Project Total: $201,696; Beta2-agonists are among the most commonly used drugs by athletes, which is related to the high prevalence of asthma and exercise induced bronchoconstriction in this population. Though use of beta2-agonists is restricted by the World Anti-doping Agency (WADA) in and out of competition, salbutamol and formoterol are allowed by inhalation within defined therapeutic thresholds. Because of potential performance-enhancing effects of systemic oral use of beta2-agonists, urinary thresholds and decision limits have been established for salbutamol and formoterol to discriminate therapeutic inhaled use from prohibited misuse. However, salmeterol while permitted, does not currently have a urine threshold (subject of our most recent successful grant) and terbutaline is not permitted, does not have a urine threshold, but is allowed under a therapeutic use exemption where it can be used supratherapeutically to impart proven performance enhancing effects. The first part of this project (Objective1) is to build on preliminary DBS work in our laboratory to develop a dried blood spot (DBS) method to measure salbutamol, formoterol, salmeterol and terbutaline in plasma, which will overcome some of the high variability associated with urine thresholds due to hydration and urine dilution. The research team at UTAS and Copenhagen has since 2015 amassed considerable pharmacokinetic data for salbutamol, formoterol, and terbutaline though WADA funded PK projects to refine beta2-urine thresholds, and the latest successful project (salmeterol) will add further acute and chronic variability data. Objective2 will focus on developing a population pharmacokinetic model based on our existing urine work. This will allow the generation of dose/route-time point nomograms, inform where deficiencies lie in urine concentration as an indicator of prohibited beta2-agonist doping in terms of confidence intervals, and highlight the areas (eg time points) where DBS methods can be best applied in future research with the objective of refining beta2-doping controls. Funded by: World Anti-Doping Agency - Grant ($201,696); University of Tasmania.
  • GRANT
    Development of a non-invasive blood sampling technique to assess paracetamol toxicity severity and response to treatment
    1 Jan 2022 - 30 Apr 2023
    People funded by this grant:
    • Veal F,
    • Patel R,
    • Jacobson G,
    • Nichols D,
    • Wanandy T
    Project Total: $9,812; This project involves development of a simple, minimally invasive Volumetric Absorptive Microsampling (VAMS) analysis of paracetamol and alanine aminotransferase (ALT) levels to provide easier and safer management of patients with paracetamol toxicity due to overdose. Funded by: Royal Hobart Hospital Research Foundation - Grant-Incubator ($9,812); University of Tasmania.
  • GRANT
    Evaluation of urine thresholds for salmeterol
    1 Apr 2021 - 30 Sep 2025
    People funded by this grant:
    • Jacobson G
    Project Total: $239,159; Beta2-agonists are among the most commonly used drugs by athletes, which is related to the high prevalence of asthma and exercise induced bronchoconstriction in this population. Though use of beta2-agonists is restricted by the World Anti-doping Agency (WADA) in and out of competition, salbutamol and formoterol are allowed by inhalation within defined therapeutic thresholds. Because of potential performance-enhancing effects of systemic oral use of beta2-agonists, urinary thresholds and decision limits have been established for salbutamol and formoterol to discriminate therapeutic inhaled use from prohibited misuse. However, while the introduction of urinary thresholds and decision limits for salbutamol and formoterol is an innovative way to avoid excessive use by athletes and to lessen the economic burdens associated with therapeutic use exemption (TUE) applications, no thresholds exist for salmeterol which results in many Anti-Doping Rule Violations (ADRVs) per year . This project focuses on developing thresholds for salmeterol where there is currently no urine threshold. Funded by: World Anti-Doping Agency - Grant ($239,159); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Pre-clinical toxicity assessment of test compounds
    1 Jan 2019 - 1 Jul 2020
    People funded by this grant:
    • Guven N,
    • Jacobson G
    Project Total: $8,677; This project will assess the short-term toxicity of 12 test compounds for Martha Jane Medical. Funded by: Martha Jane Medical ($8,677); University of Tasmania.
  • GRANT
    Factors affecting pharmacokinetics of inhaled salbutamol in athletes: Application of 4O-sulfate metabolite analysis to improve predictive value of AAFs
    4 Oct 2018 - 4 Oct 2020
    People funded by this grant:
    • Hostrup M,
    • Jacobson G
    Project Total: $207,087; Funded by: World Anti-Doping Agency - Grant; University of Copenhagen; University of Tasmania.
  • GRANT
    Exosome proteomics to detect biomarkers of erythropoietin (EPO) use in athletes
    10 Jan 2018 - 30 Jun 2025
    People funded by this grant:
    • Jacobson G,
    • Wilson R,
    • Hostrup M,
    • Bangsbo J
    Project Total: $186,727; Erythropoietin (EPO) is a 30 kDa glycoprotein hormone that controls red blood cell production, and is typically used to treat anemia resulting from chronic kidney disease. EPO is mainly produced in the kidneys, with production stimulated by hypoxia, with this hypoxia usually determined by red blood cell levels in the circulation. EPO is secreted into the plasma and binds to targets in the bone marrow (a 72 kDa receptor) which increases the ability of the marrow to produce more erythrocytes, and hence oxygen carrying capacity. There are a rapidly growing number of erythropoietin stimulating agents (ESAs) prohibited under S2 of the WADA Prohibited List, including erythropoietin and darbepoetin-alfa, as well as a plethora of hypoxia-inducible factor stabilisers (HIFs), EPO mimetic peptides such as peginesatide, and new third generation ESAs entering the market such as continuous erythropoietin receptor activators (CERA) including methoxy polythyethylene glycol-epoetin beta (Micera). This diverse range of compounds and development of new third generation agents highlights the difficulty in detection of these agents, and supports the rationale for platform -omics technologies for the development of biomarkers for detection of ESAs. There is conclusive evidence that EPO and ESAs more generally are performance enhancing in endurance sport. Sports such as distance running, cycling and cross country skiing where performance is reliant on delivery of oxygen to the skeletal muscles. The performance enhancing effects of recombinant human EPO (rhEPO) administered at relatively modest doses can result in a 6-12% increase in maximum oxygen carrying capacity, and also increase the time to exhaustion by as much as 50% at a given oxygen carrying capacity. rhEPO doping detection is problematic for many reasons. Firstly, EPO is endogenous and discrimination between the body's natural EPO and increased EPO through doping with administration of rhEPO is difficult; endogenous EPO may also be raised through doping with a variety of ESAs as well as indirect methods using the ever expanding class of HIFs. Secondly, the effects are profound with significant performance gains in endurance sports even after a washout of the EPO doping agent in terms of weeks. The specific detection of ESAs is currently based on two different approaches, the direct detection of exogenous agents and indirect detection of specific biomarkers, which is particularly promising with newer -omics approaches. Indirect evidence of rhEPO use is based on analysis of blood parameters including hemoglobin hematocrit and is contained in the Athlete Biologic Passport (ABP) but is limited in ability to provide smoking gun? conclusive evidence. Although WADA publishes criteria in an attempt to ensure harmonization between laboratories, alarmingly, a significant study demonstrated very poor agreement between two accredited laboratories which was worse during the maintenance and washout periods. The project will study the proteome of extracellular vesicles called exosomes, with the objective of identifying biomarkers of rhEPO use. The application of proteomics to exosomes isolated from blood is an exciting area research. By applying nanoflow LC-MS/MS proteomics approaches to exosomes, one of the greatest limitation of current blood proteomics for doping biomarkers is overcome - the avoidance of high abundance plasma proteins. The study will consist of a physiological intervention tria Funded by: World Anti-Doping Agency - Grant ($186,727); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Isolation and synthesis of potential new therapeutic agents from Hemp (Cannabis sativa) and their biological evaluation
    1 Jan 2018 - 30 Jun 2024
    People funded by this grant:
    • Smith J,
    • Jacobson G,
    • Guven N,
    • Bissember A
    Project Total: $105,000; Cannabis and cannabis extracts have been reported to have beneficial applications to many indications including the management of seizures, pain, cancer and appetite amongst others. One problem has been the illicit nature of the material which results in lack of control of the dose and chemical profile of material which can be due to different plant varieties, growing conditions, extraction preparation and mode of delivery. This project aims to adopt a drug discovery approach to provide solid evidence for the effect of different cannabinoids by isolating the individual components for thorough evaluation of any therapeutical applications. In this way, clear dose dependant activity can be studied and protocols for the prescription of cannabinoids can be developed that are in-line with modern pharmaceutical procedures. This will also be the start point for the development of novel semi-synthetic cannabinoids that will allow us to develop structure activity relationships for different indications. This potentially extends the scope of the medicinal cannabis industry to be a raw material for the synthesis of active non-natural derivates similar to the semi-synthetic opiates. Funded by: Martha Jane Medical ($105,000); University of Tasmania ($45,000).
  • CONSULTANCY/CONTRACT RESEARCH
    Omeprazole formulation pharmacokinetics and pharmacodynamics in horses
    1 Jan 2018 - 31 Dec 2018
    People funded by this grant:
    • Jacobson G
    Project Total: $33,460; Omeprazole is used for the treatment and prevention of equine gastric ulcers in horses, however, administration of veterinary gels and tablets can be problematic. This is a biopharmaceutics project which focuses on the pharmacokinetics of a novel granule formulation administered to horses to improve ease of dosing and impact on the animal. Blood levels of omeprazole will be analysed from pharmacokinetic time course studies and compared to existing omeprazole products. The pharmacodynamics effects have been measured by gastric pH and relationship with PK factors will be explored. The euqine veterinary phase of the study has been completed by collaborators at Charles Sturt University (Wagga). Funded by: Equestra Pty Ltd ($33,460); University of Tasmania.
  • GRANT
    Investigating enantioselectivity of terbutaline and the application to doping control
    31 Oct 2017 - 31 Oct 2019
    People funded by this grant:
    • Jacobson G,
    • Hostrup M,
    • Nichols D,
    • Walters H
    Project Total: $126,133; Beta2-agonists are among the most commonly used drugs by athletes, which is related to the high prevalence of asthma and exercise induced bronchoconstriction in this population. Though use of beta2-agonists is restricted by the World Anti-doping Agency (WADA) in and out of competition, salbutamol, salmeterol, and formoterol are allowed by inhalation within defined therapeutic thresholds. Because of potential performance-enhancing effects of systemic oral use of beta2-agonists, urinary thresholds and decision limits have been established for salbutamol and formoterol to discriminate therapeutic inhaled use from prohibited misuse. However, while the introduction of urinary thresholds and decision limits for salbutamol and formoterol is an innovative way to avoid excessive use by athletes and to lessen the economic burdens associated with therapeutic use exemption (TUE) applications, no thresholds exist for salmeterol and terbutaline. Especially for terbutaline, a urine threshold is relevant, since high dose inhalation and oral ingestion of terbutaline may enhance sprint performance and muscle strength when used acutely and for a longer duration. This project focuses on two ongoing research areas of beta2-agonists; salmeterol where there is currently no urine threshold, and terbutaline, a short acting beta2-agonist widely used in Europe but currently prohibited, which accounts for 76% of adverse analytical findings (AAFs) of beta2-agonists in doping control. Funded by: World Anti-Doping Agency - Grant ($126,133); University of Tasmania.
  • GRANT
    To investigate the use of the nutraceutical supplement Thompsons Super Bioflavonoid Complex to reduce blood glucose levels in patients with type 2 diabetes as an alternative to prescription based glip
    1 Jan 2017 - 31 Dec 2019
    People funded by this grant:
    • Jacobson G,
    • Burgess J,
    • Al-Aubaidy H
    Project Total: $15,088; This study will investigate the potential of commercially available nutraceutical supplements (Thompson's Cholesterol Manager, 500 mg/tablet, two tablets/day) to reduce blood glucose levels in patients with type 2 diabetes mellitus (T2DM). The action of these supplements is thought to be similar to the dipeptidyl peptidase-4 (DPP-4) inhibitor group, also known as gliptins, which are second line anti-diabetic drugs after metformin and sulfonylureas. The gliptins block the action of DPP-4, an enzyme which inhibits a group of gastrointestinal hormones called incretins. Funded by: Tasmanian Community Fund - Grant ($15,088); University of Tasmania.
  • GRANT
    Enantioselective pharmacokinetics of formoterol and application to doping control
    12 Oct 2015 - 30 Jun 2019
    People funded by this grant:
    • Jacobson G,
    • Walters H,
    • Nichols D
    Project Total: $195,350; The objectives of this project are to improve windows of detection of formoterol doping using enantioselective urine analyses. Funded by: World Anti-Doping Agency - Grant ($195,350); University of Tasmania.
  • GRANT
    Enantioselective pharmacokinetics of salbutamol and application to doping control
    31 Mar 2014 - 31 Oct 2017
    People funded by this grant:
    • Jacobson G,
    • Walters H
    Project Total: $139,880; We will apply our advanced analytical technique that can measure both R- and S-salbutamol in urine, to samples from patients treated with either oral or inhaled therapy over the course of a week. The project will validate the benefits, namely increased sensitivity and reduced false positives and false negatives, of measuring R- and S-salbutamol enantiomers. This will allow to better discriminate between oral and inhaled salbutamol. Funded by: World Anti-Doping Agency - Grant ($139,880); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Chemika impurity characterisation - ICH guidelines
    1 Jan 2014 - 1 May 2016
    People funded by this grant:
    • Jacobson G,
    • Davies N,
    • Wilson R,
    • Horne J,
    • Smith J
    Project Total: $8,794; This project will identify degradation products that arise during routine quality control assays as part of compliance with ICH guidelines. Degradation products will be identified using a three step process of UPLC with low resolution MS and fractionation and purity testing, followed by high resolution MS (orbitrap), with subsequent NMR. Funded by: Chemika Pty ltd ($8,794); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Enantioselective salbutamol analysis in blood of COPD patients
    1 Jan 2014 - 31 May 2015
    People funded by this grant:
    • Jacobson G
    Project Total: $4,637; Coexisting heart failure in patients with chronic obstructive pulmonary disease (COPD) is common, but often overlooked. Biomarkers of heart failure, such as brain natriuretic peptide (BNP) have been shown to predict mortality in COPD patients, although the mechanism behind this remains unclear. This study explores the mechanism that links cardiac dysfunction and COPD by studying the trends of cardiac biomarker levels in COPD patients and the correlation with clinical and cardiac functional assessments, and survival. This is a prospective study of COPD patients presenting with acute exacerbations, with no symptoms or signs suggesting acute coronary syndrome or acute pulmonary oedema. The project aims to recruit these participants when they are hospitalised and follow them up for 12 months. Participants will be reassessed during convalescence from these exacerbations (30-days from hospitalisation). Data including clinical, laboratory and cardiac functional findings will be collected during episode of acute exacerbation and during convalescence. Cardiac biomarkers will be measured on presentation, at 12 hours, at 72 hours (or on discharge, whichever is earlier) and during convalescence. The project will then investigate the trends of cardiac biomarkers correlated with the changes in clinical and cardiac functional assessments. The trends of cardiac biomarkers in patients with hypercapnic respiratory failure receiving non-invasive ventilation (NIV) will also be studied. Research will assess whether high levels of cardiac biomarkers at exacerbations correlate with serum beta-agonist levels. This will elucidate if the changes in cardiac biomarkers during acute exacerbation of COPD are associated with deterioration in cardiac function and the nature of this change in cardiac function (right or left ventricle). Simultaneous measurement of cardiac biomarkers and serum beta-agonist levels will address one of the potential explanations for the link between COPD exacerbations and cardiac dysfunction. The findings of this study may influence the treatment of cardiac disease in COPD patients. Funded by: Waikato Hospital ($4,637); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Medication stability in the Pacific Islands
    1 Jan 2014 - 31 Dec 2015
    People funded by this grant:
    • Jacobson G
    Project Total: $16,364; There are limited facilities in Pacific Island countries for pharmacovigilance and quality assurance services and most do not have any formal regulatory body (such as the Therapeutic Goods Administration in Australia) that approves medicines imported into the country. Quality is also confounded by cost and limited supply whereby drugs may need to be used beyond expiry date, as well as storage facilities and transport logistics in hot and humid environments; this can lead to medicines that may not be optimal when dispensed to patients. Even more concerning is the potential link between poor quality or ineffective medications and the emergence of resistance to antibiotics including anti-tuberculosis drugs. The project will undertake the chemical analysis of a range of common antibiotic drug batches at central storage facilities (including antibiotic tablets) using USP/BP testing with HPLC. These data will be used for research purposes; to assess the quality of medications in these nations building on previous research and provide data for the development of a drug storage and quality repository. Funded by: Dr Simon Quilty ($16,364); University of Tasmania.
  • GRANT
    Zebrafish: Pilot Applications in Muscle and Angiogenesis
    1 Jan 2012 - 31 Dec 2012
    People funded by this grant:
    • Jacobson G
    Project Total: $5,000; Funded by: University of Tasmania - Grant-Research Enhancement (REGS); University of Tasmania ($5,000).
  • GRANT
    Investigations of the Chemical and Physical Stability of Iron Polymaltose Intravenous Infusion
    6 Sep 2011 - 30 Dec 2012
    People funded by this grant:
    • Wanandy T,
    • Patel R,
    • Randall C,
    • Jacobson G,
    • Holmes S
    Project Total: $6,364; Funded by: Royal Hobart Hospital Research Foundation - Grant-Research ($6,364); University of Tasmania.
  • GRANT
    Development of a Simple and Effective Ion-chromatagraphic Analysis for the Separation and Identification of Non-anticoagulant fractions of Enoxaparin
    1 Jan 2011 - 30 Jun 2012
    People funded by this grant:
    • Patel R,
    • Hutchinson J,
    • Johns C,
    • Jacobson G,
    • Narkowicz C
    Project Total: $6,950; Funded by: University of Tasmania - Grant-Cross Theme; University of Tasmania ($6,950).
  • GRANT
    Purchase of a new generation fast mapping Raman system
    1 Jan 2011 - 31 Dec 2011
    People funded by this grant:
    • Kamenetsky V,
    • Breadmore M,
    • Vickers J,
    • Jacobson G,
    • McGuinness D
    Project Total: $240,000; The new fast imaging Raman system will be used to satisfy the research needs of a wide range of research projects within the chemical, health, pharmaceutical, material and earth sciences at UTAS. The facility is expected to substantially enhance the research outcomes of several internationally renowned researchers at UTAS. Funded by: Australian Research Council - Grant-Linkage Infrastructure ($240,000); University of Tasmania.
  • GRANT
    The Potential Role of Human Papilloma Virus in Short and Long Segment Barrett's Oesophagus and the Development of Dysplasia
    1 Jan 2011 - 31 Aug 2013
    People funded by this grant:
    • Rajendra S,
    • Snow E,
    • Ball M,
    • Robertson I,
    • Jacobson G
    Project Total: $63,636; Funded by: Clifford Craig Foundation - Grant ($63,636); University of Tasmania.
  • GRANT
    Identifying Novel Markers of Neonatal Sepsis
    1 Jan 2010 - 17 Dec 2010
    People funded by this grant:
    • De Paoli T,
    • Jacobson G,
    • Lee W,
    • Narkowicz C,
    • Vervaart P
    Project Total: $7,273; Funded by: Royal Hobart Hospital Research Foundation - Grant-Starter; University of Tasmania.
  • GRANT
    Purchase of an ultra-performance liquid chromatograph-triple quadrupole mass spectrometer
    1 Jan 2010 - 31 Dec 2010
    People funded by this grant:
    • Davies N,
    • Reid J,
    • Canty A,
    • Potts B,
    • Tamplin M
    Project Total: $200,000; Funded by: Australian Research Council - Grant-Linkage Infrastructure ($200,000); University of Tasmania.
  • CONSULTANCY/CONTRACT RESEARCH
    Walter and Eliza Hall Fungal Screening Project
    23 Nov 2009 - 31 Dec 2010
    People funded by this grant:
    • Jacobson G,
    • Narkowicz C
    Project Total: $5,434; Funded by: Walter and Eliza Hall Institute of Medical Research ($5,434); University of Tasmania.
  • GRANT
    Drug Discovery, Biotechnology and Bridging the Gap using an Intermediary: Pilot Application to Novel Flavonoids with Potential to Reduce Cardiovascular Disease Risk
    1 May 2009 - 31 Dec 2009
    People funded by this grant:
    • Jacobson G,
    • Geraghty D,
    • Narkowicz C,
    • Hilder E
    Project Total: $19,799; Funded by: University of Tasmania - Grant-Cross Theme; University of Tasmania ($19,799).
  • GRANT
    Pilot Study of Gene Expression & Protein Regulation in Barrett's Oesophagus and Oesophageal Adenocarcinoma
    1 Jan 2009 - 30 Jan 2010
    People funded by this grant:
    • Jacobson G,
    • Rajendra S,
    • Snow E,
    • Ball M
    Project Total: $8,761; Funded by: Clifford Craig Foundation - Grant ($8,761); University of Tasmania.